


Factsheet

U.S. Tabelecleucel Timeline

Last updated: March 05, 2026

Tabelecleucel is seeking approval in the U.S. to treat patients with Epstein-Barr virus–positive post-transplant lymphoproliferative disease or disorder (EBV+ PTLD) after at least one prior line of therapy. The safety and efficacy profile of tabelecleucel therapy has not been approved by the U.S. Food and Drug Administration.



As of February 2026, **over 120 patients** have been treated commercially outside of the U.S.